President Trump nominated White House domestic policy aide Dr. Heidi Overton as FDA commissioner on August 18-19, 2026, following the May resignation of Marty Makary and months of acting leadership by Kyle Diamantas. Overton’s role in the administration’s Make America Healthy Again agenda, including a recent executive order on childhood vaccines, has drawn immediate opposition from Senate HELP Committee Chair Bill Cassidy, who cited concerns over her managerial experience and vaccine policy positions as potential barriers to confirmation. Senate Democrats have also criticized the nominee. Confirmation requires a committee vote and full Senate approval in a narrowly divided chamber, with precedents like the recent CDC confirmation showing procedural delays possible. No hearings have been scheduled yet.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$14,094 Vol.
September 30
21%
October 31
35%
November 30
36%
December 31
40%
$14,094 Vol.
September 30
21%
October 31
35%
November 30
36%
December 31
40%
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
Market Opened: Aug 20, 2026, 5:43 PM ET
Resolver
0x65070BE91...If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
Resolver
0x65070BE91...President Trump nominated White House domestic policy aide Dr. Heidi Overton as FDA commissioner on August 18-19, 2026, following the May resignation of Marty Makary and months of acting leadership by Kyle Diamantas. Overton’s role in the administration’s Make America Healthy Again agenda, including a recent executive order on childhood vaccines, has drawn immediate opposition from Senate HELP Committee Chair Bill Cassidy, who cited concerns over her managerial experience and vaccine policy positions as potential barriers to confirmation. Senate Democrats have also criticized the nominee. Confirmation requires a committee vote and full Senate approval in a narrowly divided chamber, with precedents like the recent CDC confirmation showing procedural delays possible. No hearings have been scheduled yet.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions